New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 8, 2014
13:00 EDTSNSSSunesis price target raised to $15 from $12 at Roth Capital
Roth Capital raised Buy rated Sunesis' price target to $15 from $12 based on positive Phase I/II combination data with vosaroxin in older front line AML patients announced at AACR.
News For SNSS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2014
12:23 EDTSNSSSunesis December calls active
Subscribe for More Information
07:07 EDTSNSSSunesis publishes REVEAL-1 trial results
Subscribe for More Information
November 19, 2014
07:05 EDTSNSSSunesis publishes vosaroxin Phase 1b/2 AML trial results
Subscribe for More Information
November 18, 2014
07:37 EDTSNSSStifel to hold a conference
Subscribe for More Information
November 17, 2014
11:56 EDTSNSSSunesis jumps after announcing plans to present data from VALOR trial
Subscribe for More Information
November 14, 2014
16:24 EDTSNSSBiotechnology Value Fund reports 5.1% passive stake in Sunesis

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use